Good day everyone, welcome to the Mercury Systems second quarter fiscal 2023 conference call. Today's call is being recorded. At this time, for opening remarks and introductions, I'd like to turn the call over to the company's Executive Vice President and Chief Financial Officer, Mike Ruppert. Please go ahead, sir.
Good afternoon, and thank you for joining us. I hope you've had the chance to review the press releases we issued earlier this afternoon. If not, you can find them on our website at mrcy.com. The slide presentation that Mark and I will be referring to is posted on the investor relations section of the website under events and presentations. With me today is our President and Chief Executive Officer, Mark Aslett. I'm also very pleased to welcome Michelle McCarthy to the call. Serving as Mercury's Senior Vice President and Chief Accounting Officer for the past five years, Michelle has been an active and valuable member of our leadership team. I'm looking forward to working closely with Michelle in her new position as Interim Chief Financial Officer to ensure a seamless transition prior to my departure in February.
Turning to slide two in the presentation, I'd like to remind you that today's presentation includes forward-looking statements, including information regarding Mercury's financial outlook, future plans, objectives, business prospects, and anticipated financial performance. These forward-looking statements are subject to future risks and uncertainties that could cause our actual results or performance to differ materially. All forward-looking statements should be considered in conjunction with the cautionary statements on slide two in the earnings press release and the risk factors included in Mercury's SEC filings. I'd also like to mention that in addition to reporting financial results in accordance with generally accepted accounting principles or GAAP, during our call, we will also discuss several non-GAAP financial measures, specifically adjusted income, adjusted earnings per share, adjusted EBITDA, free cash flow, organic revenue, and acquired revenue.
A reconciliation of these non-GAAP metrics is included as an appendix to today's slide presentation and in the earnings press release. I'll now turn the call over to Mercury's President and CEO, Mark Aslett. Please turn to slide three.
Thanks, Mike. Good afternoon, everyone, and thanks for joining us. Typically, I'd start our prepared remarks with a review of our results for the quarter. However, given the other news we've announced today, I'll begin with key takeaways from those announcements. I'll then review the business, Mike will cover our financial results and guidance, and then we'll open it up to your questions. The board's decision to initiate a review of strategic alternatives underscores our commitment to exploring all available avenues to enhance shareholder value. We've engaged two leading investment banks to pursue a range of options, including a potential sale. During the board's evaluation, we'll continue to execute on our strategic plan for growth and value creation. As you know, we need to let this process play out, and as such, we won't have further comment on it today.
I want to emphasize that there can be no assurance that a transaction will result from the review. We also don't intend to disclose developments relating to this process unless and until the board has approved a specific agreement or transaction or has terminated its review. Let me say a few words about Mike. As you saw from our announcement, Mike has decided to step down from Mercury to accept an opportunity at a privately held company headquartered in Virginia, where he and his family reside. Mike has been a great partner for the past eight years. He's made significant contributions to Mercury, including helping drive our M&A strategy and many acquisitions. Mike, on behalf of myself and the entire Mercury team, we wish you all the best in your new role. We've initiated a search for a permanent successor with the assistance of a leading executive search firm.
We're fortunate to have a deep bench of talent on our finance team during this transition period. In addition to Michelle McCarthy's appointment as interim CFO, Nelson Erickson, Senior Vice President of Strategy and Corporate Development, will formally assume responsibility for investor relations. Last week, we also announced that Vivek Upadhyaya, who's joined Mercury as our Vice President of Financial Planning and Analysis, further bolstering our team. Over the coming weeks, Mike will work closely with Michelle, Nelson, Vivek, and I to ensure a seamless handoff. With that, let's discuss our second quarter results. Turning to slide four. Mercury's second quarter revenue was in line with our guidance, growing 4% year-over-year. More importantly, we returned to organic growth and generated positive cash flow in the quarter. GAAP net loss and loss per share, as well as adjusted EBITDA and adjusted earnings per share, fell short of guidance.
This was primarily due to an unforeseen delay in funding to our customer for a large FMS program. Absent this delay, which reduced Q2 revenue and margin by $10 million and $7 million respectively, our results would have been at or above the high end of our Q2 guidance. The delay resulted in lower Q3 guidance also, as an additional $10 million of revenue and $7 million of margin moved to fiscal 2024. We're obviously disappointed with the delay and the short-term impacts anticipated for this fiscal year. This is a large program, and the timing is outside of our immediate control.
Our customer is confident that their funding issues will ultimately be resolved, allowing us to recognize the entire $20 million in revenue and $14 million of margin early in Mercury's new fiscal year. Working with the customer, we've rotated in other related opportunities that we expect will partially offset the impact of this delay in the second half of fiscal 2023. We consider the back half in our full fiscal year guidance, we're shifting our outlook to incorporate this program timing and the prolonged supply chain impacts, resulting in program delays and inefficiencies which are temporarily affecting margins. We believe that revenue is currently trending above the midpoint of our fiscal 2023 guidance, while net income and adjusted EBITDA are now expected to be towards the low end. We're in our fourth fiscal year dealing with these impacts.
In addition to program delays and related inefficiencies, we continue to face long semiconductor lead times, tight labor market, and inflation. These challenges, however, are not related to end market demand, which remains strong. They're largely timing related, they're short term, and they're not unique to Mercury. We continue to execute on our plan to control what we can in this environment, and we're optimistic about the future given our current positioning. Mercury's bookings for Q2 increased 14% year-over-year, the largest being F-35, F/A-18, LTAMDS, and a classified C2 program. At nearly $60 million, the F-35 order for advanced microelectronics capabilities was the largest booking in the company's history. Driven by the growth in bookings, our book-to-bill was 1.18 in the quarter and 1.16 over the last 12 months.
Backlog grew 17% year-over-year to a record $1.12 billion, which positions us well for future growth. Despite the FMS customer funding delay, our Q2 revenue increased 4% year-over-year. Organic revenue turned positive, growing 1% versus a 13% decline in Q2 of fiscal 22. We expect to return to organic growth for the year as a whole, as expected. Our largest revenue programs in the quarter were F-35, F-16, SDA Tranche Tracking Layer, P-8, and THAAD. Q2 GAAP net income was negative, and adjusted EBITDA declined year-over-year. Both were below guidance, primarily due to the FMS customer funding delay. Although revenue is trending above our fiscal 23 guidance midpoint, other financial measures, including adjusted EBITDA, are trending toward the low end, as I said, largely due to program delays and related inefficiencies. We believe these impacts are temporary in nature.
We expect margins to increase as supply chain conditions begin to improve and as we realize further benefits from 1MPACT and the continued shift in our program mix from development to production. Operating and free cash flow for Q2 were positive, a substantial improvement sequentially. We expect to deliver breakeven to slightly positive free cash flow for FY 2023, including the impact of the R&D tax legislation. Turning to slide five. The Defense Appropriations Bill was approved after the midterm elections as expected, resulting in substantial spending increases in response to national security threats. The House GOP rules package adopted this month and the reported deal between Speaker McCarthy and the Freedom Caucus create risk to government FY 2024 discretionary spending, including defense. An extended budget continuing resolution appears to be the base case scenario for GFY 2024, including the potential for a full year CR.
However, although risk does exist, we don't expect Congress to approve a reduction in DoD appropriations. Given the geopolitical challenges we face, there appears to be strong underlying bipartisan support for increased defense spending. Looking ahead longer term, we believe the defense spending outlook remains positive both domestically and internationally, and that Mercury is well positioned to benefit in this environment. The growth in demand for the compute capability onboard military platform shows no sign of slowing. We also stand to benefit from the ongoing push for platform electronification. We believe that we're well positioned to continue to benefit from long-term industry trends. These include supply chain delayering and reshoring, as well as increased outsourcing at the subsystem level. Our addressable market has increased substantially, largely driven by our strategic move into mission systems and the potential to deliver innovative processing solutions at chip scale.
Our model, sitting at the intersection of high tech and defense, positions us well. Turning to slide six. The industry environment continues to be challenging in the short term. Despite incremental improvement in the second quarter, supply chain constraints continue to affect program timing and efficiency. Mercury Systems' sophisticated end-to-end processing platform powers some of the most critical Class A and B missions. High-end processing represents about 70% of the business. This is where Mercury Systems likely has the largest opportunity to grow over the next five years. Prior to the pandemic, semiconductor processor lead times were 10-12 weeks. They increased rapidly in the second half of fiscal 2021 and now range from 36-72 weeks.
Although current lead times on average are slightly shorter than in Q1, we don't expect to see a significant improvement until the second half of fiscal 2024. Semiconductor inflationary pressures remain a challenge as well. Semiconductors equate to 38% of our direct supplier spend, far more than our peers, we believe. We're making good progress in mitigating the impact of higher semiconductor costs. As part of our Impact program, we established a centralized procurement organization that's enabled us to improve our purchasing efficiency while helping us deal with the effects of supply chain disruption. We also established a pricing team, repriced standard products, and incorporated price adjustment mechanisms in our rates-based businesses and multi-year proposals. We implemented an across-the-board price increase in our microelectronics business.
Through the pandemic, we've used the strength of our balance sheet to invest in the working capital necessary to mitigate supply chain risk as best we can. As a result, we position Mercury to deliver against customer commitments and generate stronger results over time. Turning to slide seven. We believe that we've entered a multi-year period of accelerating growth and profitability. Demand is improving, as evidenced by our strong LTM bookings and record backlog. The next several years could resemble the period post-sequestration in 2013, absent a significant budget event in GFY 2024. Similar to the enhancements that we made in our business at that time, through Impact, we're strengthening our fundamentals once again. We launched Impact early in fiscal 2022, and it's evolved substantially since then. We began by streamlining our organizational structure and strengthening the leadership team and continue to do so.
We also focus on margin expansion initiatives, we're now pushing their execution deeper into the business. With the recent addition of Alan Fichera as Head of Execution Excellence and Mitch Stevison taking over our mission business last quarter, we've doubled down on these efforts, seeking to drive continuous improvement around supply chain, operations, and program execution. These areas have all been affected by the cumulative impacts of operating during the pandemic, with the resulting program delays and related inefficiencies temporarily impacting margins. We believe these headwinds will diminish as supply chain and labor market conditions continue to improve, leading to margin expansion. At the same time, we continue to focus on supply chain risk mitigation, working capital burn down, and accelerated cash release. We believe that substantial cash will move off the balance sheet as the supply chain-related impacts on the business begin to unwind.
Another initiative is R&D investment efficiency and returns. In addition, our digital transformation efforts in engineering, operations, and the back office will help improve our cost structure and give us better productivity, scalability, and efficiency over time. We're also moving on our manufacturing facility footprint strategy. We consolidate our Mesa, Arizona facility into the Phoenix site in Q2 and release two additional facilities as planned. With that, I'd like to turn the call over to Mike. Mike?
Thank you, Mark, and good afternoon again, everyone. Before I discuss our results, I do want to say a few words about my decision to leave Mercury. Mercury has been a big part of my life for the better part of a decade. Since I started at the company in 2014, we've grown the business organically, completed 15 acquisitions, and assembled a set of capabilities that uniquely position us in the defense industry. It's been a tremendous opportunity to be Mercury's CFO, working alongside Mark and the rest of our talented leadership team during this time. A few months ago, I was approached by a company that had recently been taken private, based closer to my home in Virginia. This is not something I sought out, but when the opportunity was presented to me, I felt at this point in my career it was something I had to explore.
There's never a great time for a move like this, I'm firmly committed to making this transition a success. Michelle McCarthy and I have been in lockstep for years, and I've developed our finance team, so I know how much talent there is at Mercury Systems. I wouldn't have made the decision to leave if I didn't have complete confidence in this team and in the company's ability to enhance value for all shareholders, including me. To our investors and analysts, it's been a pleasure getting to know all of you over the years. Turning to Mercury Systems' results, as always, I'll begin with our second quarter actuals and then move to our Q3 and fiscal 2023 guidance.
As Mark Aslett discussed, Mercury Systems delivered revenue in line with guidance, returning to organic growth and generating positive cash flow in Q2. Demand continues to be strong as we enter the second half.
Our 12-month backlog was up 34% compared to Q2 last year and up 10% compared to last quarter, providing us solid visibility into the remainder of the year. For fiscal 2023, we expect to deliver increased bookings versus fiscal 2022, a positive book-to-bill, a record $1 billion in revenues, and positive organic growth. As Mark said, we expect our performance to be heavily weighted to the fourth quarter. We believe that revenue is currently trending above the midpoint of our fiscal 2023 guidance, while adjusted EBITDA is trending toward the low end, as I'll discuss. Demand remains strong, supported by our position on well-funded franchise programs.
Supply chain constraints, labor availability, and inflation continue to contribute to program delays and inefficiencies. With these post-pandemic impacts persisting through fiscal 2023, we're experiencing shifts in high margin production programs, including FMS sales into Q4 and fiscal 2024, impacting Q3 and fiscal 2023 gross margin expansion as a result. Slide 8 covers the bookings, book-to-bill, backlog, and revenue growth results that Mark discussed. Worth highlighting again is the large FMS program customer funding delay that had an impact of approximately $10 million on our Q2 revenue. Given the program's high margin profile, it also impacted profitability by approximately $7 million, resulting in the adjusted EBITDA guidance miss for the quarter. This delay in customer funding reflects the nature of FMS contracting, which requires alignment between the U.S. government and the foreign government, as well as our direct customers.
This being an approved FMS deal, the delay only relates to the award timing for both our customer and Mercury. We now expect this program in our fiscal 2024. As Mark Aslett mentioned, we expect this to have an approximate $20 million and $14 million revenue and adjusted EBITDA impact to fiscal 2023, respectively. Gross margins for the second quarter were down 430 basis points year-over-year. As we expected coming into the quarter, gross margins reflected a higher proportion of lower margin development revenue as well as material and labor inflation year-over-year. Gross margins were slightly lower than expectations, driven by the FMS delay, which had an approximate 140 basis point impact on gross margins. Q2 gross margin was also impacted by incremental depreciation expense and lower absorption in the quarter, primarily due to our site consolidation efforts.
We expect to see higher gross margins in the second half of the fiscal year and especially in Q4. This is primarily a result of program mix shifts due to the high margin FMS sale, as well as execution on some of our larger development programs taking a little longer than expected in the current environment. GAAP net loss was $10.9 million for the quarter, while adjusted EBITDA was $35.7 million, down 6% from Q2 last year on lower gross margins. Our adjusted EBITDA margins were 15.5% for the quarter, down 180 basis points from 17.3% in Q2 fiscal 2022. Again, the delay in the large FMS opportunity resulted in adjusted EBITDA and adjusted EBITDA margins being below our guidance range.
Had we received this contract, adjusted EBITDA and adjusted EBITDA margins would have exceeded our Q2 guidance. Free cash flow for the second quarter was an inflow of approximately $22 million, despite delays in payments from our customers at the end of their fiscal years. Delayed payment behavior across our customer base was partially offset by receivables factoring, which we discussed last quarter. Slide 9 presents Mercury's balance sheet for the last five quarters. Our balance sheet remains strong with significant capacity under our $1.1 billion revolving credit facility. Driven by the anticipated strong cash flow generation in H2, we expect to be well-positioned to de-lever the balance sheet while continuing to invest in the business. We ended Q2 with cash and cash equivalents of $77 million and approximately $512 million of debt funded under our revolver.
At current leverage levels, the interest rate under the revolver is approximately 5%, which positions Mercury to continue to allocate capital at attractive rates. From a working capital perspective, we've invested approximately $240 million since fiscal 2021, essentially the start of the pandemic, to support performance obligations to our customers and ensure delivery on critical programs. As these obligations are completed, we expect working capital, especially unbilled receivables and inventory, to convert to cash and decrease substantially the percentage of annualized sales. Turning to cash flow on slide 10. Last quarter, we forecasted breakeven to slightly positive free cash flow in Q2. Free cash flow for the quarter was $22 million. In Q2, we did see delays of approximately $30 million in receipts from billed receivables from our customers at the end of their fiscal years. These were partially offset through factoring $20 million of receivables.
At this point in Q3, we have received the $30 million of delayed payments from our customers. Given our fiscal year timing, we did not see any impact related to the R&D tax legislation in H1, but we're now forecasting an impact in H2. I'll now turn to our financial guidance, starting with Q3 on slide 11. Forecasting in the current environment remains challenging. Our guidance incorporates, to the extent we can, potential impacts associated with the ongoing supply chain constraints and material and labor inflation headwinds. As a result of the high margin FMS program moving into fiscal 2024, coupled with the headwinds contributing to program delays and inefficiencies, H2 is more weighted to Q4 than Q3. For Q3, we currently expect revenue in the range of $245 million-$260 million.
At the midpoint, this is approximately flat growth compared to the third quarter last year. Although we remain cautious with regard to award timing, program execution, and the current industry headwinds. We expect gross margins to increase gradually in Q3 and more dramatically in Q4 as we complete execution across several of our lower margin development contracts. The revenue growth in H2, and especially Q4, is expected to be driven by higher margin production programs as well as license sales. We expect Q3 GAAP results to range from a net loss of $5.8 million to net income of $1 million. We expect adjusted EBITDA to be $40 million-$47 million, representing approximately 17% of revenue at the midpoint. As I've said, our Q3 adjusted EBITDA margins are being impacted by the delay in the FMS sale as well as a higher proportion of development contracts.
I'll now turn to our guidance for full year fiscal 2023 on slide 12. The near-term outlook across the industry remains far from certain, the demand environment continues to be strong, as highlighted by our continued bookings momentum. Balancing these two dynamics, we're maintaining our previous guidance for the year for revenue and adjusted EBITDA. From a total company revenue perspective, our guidance remains $1.01 billion-$1.05 billion in fiscal 2023. This represents 2%-6% growth year-over-year and approximately flat to 4% organic growth. Based on our current demand environment, despite the approximate $20 million slip in FMS revenue, we still expect to see fiscal 2023 revenue towards the high end of this range.
GAAP net income for fiscal 2023 is expected to be in the range of $13.9 million-$24.8 million, with GAAP EPS of $0.24-$0.44 per share. The reduction at the low end and midpoint is a function of the incremental depreciation expense in the second quarter, partially offset by lower expected stock-based compensation. We're maintaining our fiscal 2023 adjusted EBITDA guidance range of $202.5 million-$215 million, up 1%-7% from fiscal 2022. While we expect revenues at the high end of the range, we expect adjusted EBITDA to trend toward the lower end of the range. This is driven primarily by program mix, including the FMS sale, as well as supply chain-related program delays and inefficiencies also impacting adjusted EBITDA margins.
Adjusted EPS is expected to be in the range of $1.90-$2.08 per share. The reduction from our prior guidance is also a function of the incremental depreciation expense in the second quarter. From a free cash flow perspective, we're now targeting breakeven to slightly positive free cash flow for the year. This includes approximately $36 million of cash outflows related to R&D tax legislation in H2, which we've now incorporated into our guidance. Turning to slide 13, I want to briefly touch on Q4, which we expect to be a record quarter for Mercury across all key metrics. While we will not formally guide Q4 until next quarter, based on H1 actuals and our Q3 and fiscal 2023 guidance, we can arrive at an implied forecast for the fourth quarter.
Looking at the midpoints of our fiscal 2023 and Q3 guidance ranges, Q4 revenue at the midpoint would be approximately $320 million. This is an increase of approximately 11% from our record fourth quarter last year. Given our current backlog and anticipated bookings in Q3, we expect to enter Q4 with solid forward backlog coverage, which is the basis for our current guidance. GAAP net income and GAAP EPS will be approximately $47 million and $0.83 per share, respectively, at the midpoint. Q4 adjusted EBITDA would be approximately $98 million, and adjusted EBITDA margins would be approximately 31%. These results are driven by gross margin expansion, reflecting a mix weighted toward higher margin production programs and licensing revenues. We also expect adjusted EBITDA margin improvement as a result of the operating leverage we've created in the business.
From a free cash flow perspective, we expect to see a strong rebound in Q4. While Q4 would represent a record quarter across all our key metrics for Mercury, we believe we have a clear path to achieve our guidance. With that, I'll now turn the call back over to Mark.
Thanks, Mike. Turning now to slide 14. Mercury delivered strong bookings in the second quarter. We returned to organic growth and generated positive cash flow in a still challenging environment. Demand is strong and getting stronger. Our robust H1 bookings, record backlogs, and substantial forward revenue coverage provide us with good visibility into the second half of fiscal 2023. Timing, however, remains a risk in the short term as we win larger and more complex subsystem deals. Given the impact of the delays associated with the FMS program, we have a larger fourth quarter than previously anticipated. We have a high level of confidence in our ability to recognize the associated revenue and margin in the first half of fiscal 2024. As a result of the additional opportunities we've rotated into the plan, we're maintaining our fiscal 2023 revenue and adjusted EBITDA guidance.
As I said earlier, while revenue is trending above the midpoint, adjusted EBITDA is likely to come in toward the low end of guidance as a result of mix and supply chain-driven program delays and inefficiencies. For the year, we expect to deliver strong bookings weighted toward Q4. We expect a positive book-to-bill and a return to organic growth with revenue eclipsing $1 billion for the first time. This should position us well for fiscal 2024 as the supply chain conditions begin to normalize. We expect to deliver strong organic growth, margin expansion and improved cash flows as we release working capital, all of which should position us for further growth and value creation in future years. That said, the potential for disruption around the GFY 2024 budget and the timing and level of the defense appropriation present additional risk.
Looking further ahead, our outlook for the next 5 years remains strong. We expect increased defense spending domestically and internationally. We're well-positioned strategically in the right part of the market with the right capabilities on the right programs. We believe that Mercury can and will grow organically at high single-digit to low double-digit rates. In addition to organic and M&A related growth, our 5-year plan includes margin expansion driven by better execution as the industry headwinds subside, improved program and content mix, as well as 1MPACT. This should lead to stronger profitability as well as improved working capital efficiency and cash conversion. For more than a decade, we've successfully executed on our longer-term strategy. We've improved margins by growing the business organically, supplemented with disciplined M&A and full integration. As a result, we've created significant value for our shareholders and expect to continue doing so.
In closing, I'd like to recognize the Mercury team's commitment to our success and strong performance in the second quarter. My sincere thanks to all of you. Before we turn it over to Q&A, I ask that you please keep your questions focused on our earnings results. With that, operator, please proceed with the Q&A.
Thank you. If you would like to ask a question today, press star followed by 1 on your telephone keypad. If you'd like to remove your question, again, press the star one. We ask today that you limit yourself to 1 question and 1 follow-up. Thank you. Your first question comes from the line of Peter Arment with Baird. Your line is now open.
Yeah, good afternoon, Mark, Mike.
Good day
The 1MPACT program that you've, you know, you've talked about quite a bit about on this, on this call and in previous calls, I think you targeted, you know, net savings to be $30 million-$50 million when you look out, you know, to fiscal 25. Just wondering where that stands today. I know that you achieved at least $22 million in your first fiscal year. Can that still grow, just given all the efforts you've done? As the follow-up, I'll ask you now, just your confidence around kinda is there much FMS mix in the fourth quarter that could also slide out, you know, just given the, kind of the impacts that you've had from customer shifts? Thanks.
Thanks for the question, Peter. I think we're absolutely on target, you know, for the 1MPACT savings. I think the program's going extremely well. If anything, we're probably slightly ahead of schedule compared to where we thought we were going to be at this point in time. Unfortunately, I think, you know, a lot of the efforts and the results that we've delivered, you know, aren't really showing up in our financials right now because they are simply offsetting, you know, some of the headwinds that we're facing. For the programs on track and, yeah, we think there's substantial upside, you know, associated with it going forward. As it relates to FMS, you know, we do have some FMS, you know, in the fourth quarter.
As we rotated out, you know, the $20 million of revenue and $14 million of margin from Q2 and Q3. You know, we were working with the customer able to rotate in additional revenue that partially offset, you know, some of the shortfall, you know, due to the delay in funding. Yeah, there is some revenue in the fourth quarter. I haven't got the number off the top of my head. Mike, do you?
It's not something we break out specifically, but I would say, Peter, that the magnitude of the revenue we have is much lower than the $20 million of revenue and $14 million of gross margin that slipped out.
Appreciate the color. Thanks.
Your next question comes from the line of Seth Seifman with JP Morgan. Your line is now open.
Thanks very much. Good evening, guys. I guess, just on the topic of the availability of semiconductors and chips. I guess I'm wondering kind of what makes that take until the second half of 2024. You know, we saw Intel's results last week. It seems like demand in the civil economy is really drying up. You know, you would think that maybe that would free up capacity more quickly for the defense industry. What makes that take so long?
Yeah. First of all, I think it's based upon, you know, the feedback that we're getting specifically from some of those semiconductor companies based upon, you know, what they think is gonna happen in terms of the, you know, capacity and, you know, their ability to supply. You know, we did see some incremental improvements, Seth, you know, in the second quarter. You know, last quarter, you know, we were talking that the semiconductor lead times on the high end, in particular, the stuff that's coming out of TSMC and, you know, some of the high-end Intel processing, the lead times were 52-99 weeks. You know, this quarter, you know, we did see the average come down, you know, 36-72 weeks.
You know, it's still extremely long, you know, and far longer than what we saw pre-pandemic, you know, which is in the 10-12-week range. We're pleased to see the improvement and see the average coming down, but it's still got a long way to go.
All right. Okay. Okay. Thanks. Then, just as a follow-up, when we look at the data, you know, that comes out in the filing, about the sales breakdown between different types of products, different customers, is there anything there that offers a little bit more insight into the gross margin compression that we've seen, whether it's, you know, I mean, Last quarter kind of, we only have it as of the I guess, as of the September quarter so far, but, you know, fewer sales into radar applications, you know, I guess fewer sales into components, you know, more sales to Lockheed?
As we look through these different categories, is there anything about the mix that's changing that we can be aware of in terms of thinking about the gross margin and the profitability of different types of sales?
Not specifically at a macro level, Seth. I think, you know, if anything, what we are seeing, is just the cumulative effects of operating under the pandemic and, you know, the delays that we've seen on programs and the resulting inefficiencies. You know, things are taking longer. You know, we've seen cost growth, and that's clearly, you know, is what is impacting the margin. As we look forward, you know, as we've said, you know, as more of these programs kinda get out of the development phase and into production, you know, we'll start to see some, you know, mix shifts and some margin improvements there.
You know, coupled with, you know, some probably better efficiencies in supply chain, you know, so less of a headwind, and then, you know, continued benefit from 1MPACT is really what's gonna drive, you know, the margins, as we go forward. I don't know, Mike, if you would like to add anything to that.
No. I mean, Seth, you'll see the detail when the Q comes out in terms of subsystems, components, modules. I think what Mark said is correct. You're not gonna see anything there significant that's going to stand out as the driver of the margin degradation. It really is these new program starts that we've talked about. As the development programs transition, you know, over time to production, they're just taking a little longer in this environment. Then we, you know, expect that to transition in fiscal 2024. Nothing specifically that we can point to in the Q. More just around the trends that we're expecting in Q4 and in fiscal 2024.
Obviously, Seth, the, you know, the FMS program that moved, you know, that was pretty high margin based upon the capabilities that we're providing. You know, that includes, you know, IP licenses and royalties. You know, we do see a pickup of that, you know, as we're going into the second half as well. The mix, you know, in terms of capabilities and the programs really do matter. You know, it's unfortunate that, you know, the customer had this funding delay that, you know, moved the $20 million of revenue and $14 million out of the year.
Yeah. Okay. Thank you very much.
Yeah.
Your next question comes from the line of Ken Herbert with RBC. Your line is now open.
Hey, Mark and Mike.
Hi, Ken.
I, wanted to ask, yeah, Mark, on the, on the free cash flow guidance, sorry if I missed it, but as you think about sort of break even to slightly positive, call it $60 million in the second half of the year, how does that split between the third and fourth quarter? What's the guidance implied for the cadence of cash in the second half of the year?
Ken, I'll take that one. It's Mike. When we look at the second half, it is gonna be more weighted to Q4. We think Q3, prior to the R&D tax, I'll give you the split between those between Q3 and Q4. Prior to the R&D tax payments, we think Q3 is gonna look a lot like Q2, which we expected coming in prior to factoring to be break-even to slightly positive. That's what we're seeing in Q3 right now. Now that's pre the R&D tax payment, which we estimate is gonna be $23 million. In Q3, it's gonna be $13 million in Q4 to get to the $36 million that we mentioned in the prepared remarks.
What we're looking at is a free cash outflow in Q3 in the magnitude of $20 million. Q4 is gonna make up the difference as we see the higher net income, higher Op income, and we actually expect working capital in Q4 to release, especially in unbilled and inventory, which is driving the cash flow for the year.
Yeah, that's helpful. Thanks, Mike. It, it sounds like for cash earnings, or cash and earnings, obviously a pretty significant ramp in the fourth quarter. Is there any programs you'd specifically call out maybe around progress payments or anything like that we should keep in mind as significant or material swing factors in the fourth quarter? You know, that could either be potential risk or, that are obviously embedded in what's gonna help sort of hit the full year number. Seems like a pretty aggressive ramp in the fourth quarter.
Yeah.
Yeah.
Go ahead, Mike. Go ahead.
I was just gonna say, you know, it's definitely a large quarter, Ken. We, we do feel good. The, the good news as we look at it is we have, you know, good backlog coverage right now going into, to H2, and into Q4. We've got good visibility into the programs that aren't in backlog, that make up the balance of our, FY 2023 and specifically the Q4. We're entering with strong backlog coverage. A majority of the remaining, are recurring programs for which we're designed in on. We also have, and I think Mark touched on it briefly, you know, we have improved visibility and coordination into the supply chain, than we had in H1. Still risk around it, but we feel better about it.
We've got line of sight into some, you know, key execution milestones that drive revenue in Q4 on a couple of key programs. You know, there's still uncertainty in the environment, supply chain, contracting delays, things that we've talked about. We're working to control what we can. Overall, we feel good about the demand environment and the programs. We're just cautious on the items that are out of our control. Just from a profitability perspective, we obviously expect margin expansion in Q4, and you know, that's gonna drive, you know, cash flow as well.
Yeah. Ken, just following up. There's kind of five things, right? You know, the higher margin program mix in the second half, as we talked about. You know, we do have a pickup in high margin IP licenses, you know, and some royalties on various programs. We are anticipating, you know, fewer execution delays and some inefficiencies. We saw supply chain, I would say, improve incrementally, you know, in the second quarter. You know, as the conditions stabilize and as hiring continues to pick up, yeah, I think we've got fewer headwinds there. 1MPACT, I think, continues. Yeah, we've got continued savings relating to our pricing initiatives that we undertook early in the year.
You know, we've got some procurement savings and, yeah, this quarter, you know, we had some facility footprint consolidation. We've got further consolidation in Q3, that will lead to savings. Finally, you know, just obviously better absorption and better overheads leverage, largely as a result of the higher revenue. You know, although it's a big quarter, I think, you know, we, you know, we've done the work and, you know, we know what's gonna drive the, you know, the increase.
Great. Thank you for all the color.
Your next question comes from the line of Jonathan Ho with William Blair. Your line is now open.
Hi, good afternoon. Just wanted to start out with some of the delayed payments that you were seeing from your customers. You know, are you seeing that behavior maybe persist or are you sort of building that into your guidance, you know, just given some of the challenges around, you know, cash flow management that everybody's sort of facing?
Sure, Jonathan, we saw it a little bit in Q1. We talked about it on the Q1 earnings call. We saw a little bit more of it in Q2. Now remember, you know, our fiscal Q2 is our customers' year-end. We did see them managing receivables to us at the end of the quarter. As we mentioned, it was about $30 million that we saw held that was due for us in the quarter. We've received all of that already in Q3. It was just a couple of weeks or less than a week delay as they straddled their fiscal and calendar years.
Going forward, I think, you know, we've got a really good group of customers that normally pay on time. You know, we're managing that with them. We also put in the factoring facility that I mentioned, and we used it exactly for this reason, Jonathan, which was a tool that we have that's a very low cost of financing to us, in order to mitigate the impacts on our cash flow statement and our financials because of our customer behavior. You know, we feel good that we're in a position to manage it from an organic standpoint, but we also have a tool in the factoring facility should we need to use it, should we see this behavior continue.
Got it. Got it. That's helpful. You know, in terms of some of the pricing actions that you've taken, you know, how should we be thinking about like the timing and sort of the magnitude of how that flows through? Like I know there's a variety of different actions across both, you know, the pricing of services as well as products. Yeah, just any color would be helpful. Thank you.
Pricing, you know, has obviously been a, you know, one of the major elements of the 1MPACT program. We stood up a pricing center of excellence to try and drive strategic pricing and best practices in both pricing and cost estimation, depending upon, you know, the part of the business. In the commercial portfolio, you know, I think the team's done a really good job. Yeah, we're actually offsetting, you know, a significant amount of the, you know, inflationary pressures that we're seeing on the semiconductor side of things. You know, focused on value-based pricing. You know, we're looking at the discounting and the quote validity.
I think as I mentioned on the last call, you know, we did do an across-the-board price increase on our commercial products, you know, at the start of the year, that is really the major driver of offsetting the inflation pressures that we see there. Now, on the non-commercial portfolio, you know, it's slightly different, right. Here, you know, that's largely some of the, you know, cost disclosure side of the business. Here, we're really mainly focused on wherever we possibly can, you know, passing through both material and the labor inflation costs that we see, as well as, you know, trying to do a better job, you know, managing the scope creep, you know, with customers and monetizing those, as well.
Depending upon the type of contract and the, you know, what's already in backlog, you know, the ability to be able to pass through those costs, you know, obviously there could be a time difference there. I think overall, the team's doing a pretty good job. I think, you know, the inflationary headwinds, with the work that we've done, you know, aren't as, you know, detrimental to what we thought they could be coming into the year. Mike, would you like to add anything?
No, you got it.
Thank you.
Your next question comes from the line of Sheila Kahyaoglu with Jefferies. Your line is now open.
Thanks. Good evening, Mark and Mike. Thank you for the time. It seems like there's a lot going on, Mark, just both externally with the board and internally. Maybe can you just talk to us about how you're balancing all the internal factors and what you're most focused on now, you know, in terms of the business. Is it just ensuring the sales come through? Is it supply chain? If you could talk to us a little bit about that. You mentioned R&D as well.
Sure. It's a good question. I think, you know, the demand environment continues to be strong. We're still very, very focused on the top line. You know, bookings, as we said, were up 14% year-over-year. We had a 1.18 book-to-bill in the quarter, and a 1.16 over the last 12 months. You know, growing backlog 17%, you know, which gives us pretty good confidence and coverage, you know, along with the bookings that we expect in Q3 and Q4. Clearly, you know, what the team is very focused on right now, is the execution in the second half. You know, it was unfortunate that we saw those FMS delays, you know, which has made the year more back-end loaded.
We did talk about the, you know, the coverage that we've got, you know, which is far higher than what we had coming into the second half last fiscal year. You know, we're continuing to focus on mitigating the supply chain and the semiconductor lead times, you know, which continues to be a challenge, albeit incrementally improved. Hiring, I think, is better. You know, for the third quarter in a row, you know, we are actually hiring more people than, you know, are leaving. You know, but we've still got open recs along with the rest of the industry. It's important for us to continue to fill those positions as we're looking at the growth in the business going forward.
I would say that, you know, the team is very focused on just execution. You know, focused on growing the business, and focusing on continuing to deal with the cumulative effects of the pandemic, Sheila.
Sure. No, that's helpful. If I could follow up, I don't know if you mentioned this in answer to a question. The FMS sale that slipped out, you said was $20 million of sales and $14 million of earnings associated with it. Was that right?
That's correct, yes.
Okay.
Yeah. $10 million and $1 million in Q2, and the same in Q3.
Okay. It's a pretty high margin contract in terms of thinking about that.
It is. It's a mix of capabilities. Again, you know, there's hardware associated with it. You know, based upon the capability set, there's also revenues and royalties.
Great. Okay. Thank you.
Your next question comes from the line of Michael Ciarmoli with Truist Securities. Your line is now open.
Hey, good evening, guys. Thanks for taking the questions here. kind of staying on what Sheila was asking with kind of internal, external, a lot going on. Just I guess, Mark, labor's been tight to begin with. How do you think about managing talent right now, talent loss? You know, doesn't this potential announcement of strategic alternatives, I mean, can't that add to disruption and kinda take employees off, you know, the ball, you know, focusing on execution? How do you kind of think about managing that risk right now?
I mean, look, it's a possibility obviously with just what we know. But I do think that we've got a fair amount of hiring momentum, you know, inside of the company. I think there's obviously a lot of growth, you know, ahead of us and yeah, I think we're a great company to work for. I don't see necessarily a major challenge with respect to retention. On the attraction side of things, I think, you know, we're really focused on two areas. You know, one is on the direct labor side of things, and, you know, I don't really, believe that, you know, the announcements that we made this morning, or sorry, this afternoon around, you know, the potential process will have an impact there.
Yeah, probably the more challenging area is on the engineering side. Again, yeah, I think we've got a great employee value proposition and, yeah, I feel pretty confident just based upon the momentum that we're gonna be able to actually make the hires that we need.
Got it. Got it. Just to follow up, entirely separate, You talked about the demand environment. We've seen a very strong book-to-bill the last several quarters. How are you thinking about the bookings environment over the back half of the year, especially now with a budget in place?
Yeah. I think we're expecting, you know, again, strong bookings, sequentially H2 over H1, Mike. I think just with some of the recent shifts, there's probably gonna be more of the growth in the fourth quarter, just given some of the movements that we've seen. Yeah, we're expecting strong growth, you know, year-over-year with a positive book-to-bill. I think, you know, this is not a, you know, a demand issue. Obviously, the demand environment is very strong. If anything, these are kind of short-term timing issues and really, a result of the cumulative effects of the pandemic.
Got it. To be clear, you did $600 and almost 30 million in bookings second half last year. You think you guys can do better than that, is what you're saying?
Yeah. This year, if you look at, you know, H1 was far stronger than, you know, than the prior year.
Yep
... you know, the weighting of bookings was far more balanced. For the year, you know, we do expect bookings to be up substantially. You know, just given the weighting H1, H2, I think it's gonna be more of a sequential story than it is year-over-year in H2.
Got it. Got it. Helpful. Thanks, guys.
Yeah. Thanks, Mike.
Your next question comes from the line of Austin Moeller with Canaccord. Your line is now open.
Hi. Good afternoon, Mark and Mike.
Hey, Austin. How are you?
Doing great. My first question here, if we just stay on the topic of the supply chain, if we do continue to see lead times come down, I mean I know it was sort of an incremental improvement in the second quarter, but it's still notable. Do you expect you're going to be reducing inventory stockpiling if lead times continue to fall? Do you expect as we go into potentially a recession here that materials costs might come down for Mercury?
Mike, why don't you take the first and I'll take the second one?
Yeah. With regards to the balance sheet, Austin, as the supply chain normalizes, as we've discussed, we do expect to see an unwind of inventory and an increase in inventory terms. It also has been impacting our unbilled receivables, where we've been unable to deliver in some circumstances, because of long lead times or even a shortage of parts. Once that normalizes, we expect both those accounts, inventory and unbilled, to decrease, which is why we think there's, you know, stronger cash flow in Q4. Really heading into fiscal 2024, as things begin to normalize, we expect that there should be a significant reduction in working capital, again, once that supply chain normalizes.
On the semiconductor side of things, you know, clearly I think, you know, part of the semiconductor marketplace has rolled over on the lower end, largely as a result of what is going on, you know, on the consumer electronic side of things. You know, the high end, as I mentioned, is still. You know, although it's softened somewhat from a lead time, it's come down a little bit on average, it's still far longer than what it was pre-pandemic. We haven't seen much movement there at all. In fact, if anything, the prices are going the other way still. You know, the high-end semiconductors, we've seen price increases from Intel, from Xilinx, from, you know, Analog Devices. The high end pricing is still pretty challenging.
On the lower end side of things, you know, we have been able to negotiate better pricing in some parts of the market, but it's still pretty challenging out there, Austin.
Okay. Just to follow up on that, I think you said in the remarks you're sort of anticipating improvement in the lead times in the second half of fiscal year 2024. What are you seeing on your end that gives you confidence in that? Is that what's being communicated to you from TSMC and Intel, or how should we think about the timing there?
Yeah. We're, we're obviously not in contact, you know, with TSMC directly. We're dealing with, you know, the companies whose chips are actually fabbed in the TSMC facility, you know, as well as, you know, other facilities offshore, you know, from various other companies. The, you know, the 36-72-week lead times that I mentioned, you know, is, you know, what we are seeing right now with respect to the parts that we've got on the high end of semiconductors. These are the logic devices, the FPGAs that go into many of our processing systems. We're getting the input from our suppliers as to, you know, what they're seeing, and, you know, we'll see what happens, as things continue.
Hopefully, they continue to come down.
Okay, great. Thanks for diving into the details there.
Thanks, Austin.
Your next question comes from the line of Noah Poponak with Goldman Sachs. Your line is now open.
Hey, good evening, everyone. Mike, thanks for spending time with us and working with us over the years, and all the best, going forward.
Thanks, Noah.
You know, it's been a funky, you know, year and a half or two years. If I, if I kinda zoom out and try to sorta recalibrate for it, the top line actually never really gotten that bad. You know, there's kinda three distinct quarters where the revenue decline is a little more severe, and then a few where it's really actually not that severe, and that's kind of it.
Mm-hmm.
Relative to that, you know, the margin change is more significant and pretty volatile in the year. The cash flow change is very significant, and the working capital in particular. I guess, how do I square all of that when you kinda look back at this 18 to 24-month window? Why is the profitability and the cash flow so much more volatile than the top line?
Sure. I think, you know, it's a good question, Noah. It has been a, you know, a few years and, you know, each year has been slightly different in terms of the impact. You know, bookings, you know, bottomed out, I think in the third quarter of fiscal year 2021. Organic growth actually bottomed out this quarter. We had 1% organic growth in Q2 versus a 13% decline. You know, we've got, you know, various metrics beginning to head in the right direction. You know, if you look at the margin profile, it's really, I think as a result of kind of what's happened a little bit with respect to linearity.
you know, over the course of the pandemic, as lead times dramatically increased, and as we started to see, you know, just the perturbations in the supply chain in terms of supply decommits, you know, it obviously created, you know, it pushed more of the business into H2, you know, which obviously had an impact on margins in the first half. And then you've got the general inefficiencies associated with just the, you know, the impacts that we've been facing. you know, the margin pressure is pretty much all related to the pandemic and the effects associated with that. There's nothing underlying the business.
If anything, I think as we look forward, you know, as a result of, you know, the shift from development into production, profitability mix, as well as, you know, the ongoing benefits of 1MPACT, we see substantial opportunities for margin growth. Then the cash flow, I think as you know, is very much tied up with, you know, the balance sheet. You know, again, as the supply chain conditions, you know, became far more challenging, as lead times actually increased, you know, we ended up, you know, leveraging the balance sheet to make sure that wherever possible we could meet our customer commitments, you know, on an inventory side.
Again, on the unbilled side of things, that's where we saw, you know, the effects of part shortages and, you know, which tied working capital up in unbilled. Ultimately cash, you know, it collects everything and that's where we saw the greatest volatility. Mike, I don't know if you wanna jump in there?
Yeah. No, I think that's, I think Mark hit it. I mean, just giving some numbers, if you look back, you know, and just starting with adjusted EBITDA as the measure of profitability, you look back fiscal 2019, 2020, 2021, we were all around 22%. We came into fiscal 2022, we dropped down to 20%. You know, I think we talked about publicly that we had about, you know, 70 basis points or so as a result of supply, you know, chain inflation. You look at fiscal 2023 and where our guide is, it's, you know, 20.3% at the midpoint. We probably have a similar 70 basis point inflation impact. Those two, you know, would put you at 21%.
The reduction there from 22% from 19 to 21, down to 21 and 22 and 23, is really a result of the development programs that we've talked about. As Mark said, when we look at EBITDA margins going forward, and we'll guide fiscal 24, you know, when we get to our Q4, we do see the opportunity for EBITDA margin expansion. I don't think anything's fundamentally changed in the business from a profitability perspective. When you look at gross margins, there's a lot more movements. As you know, we had COVID expenses in fiscal 21, running through our gross margins. We've had some, you know, movements between development programs and production on a quarterly basis. We've had the Physical Optics acquisition, which impacted gross margins.
On, again, on a quarterly basis, things like this FMS sale, you know, our program mix, you know, makes, you know, creates some volatility. Again, going to EBITDA, looking out over the long term, you know, a couple of key metrics, and we think the profitability of the business, you know, structurally, is the same with opportunity for upside in fiscal 2024 and beyond.
Okay. I'll leave it there. I appreciate the color. Thank you.
Mr. Aslett, it appears there are no further questions. I'd like to turn the call back over to you for any closing remarks.
Okay. Well, thank you very much for taking the time to join us this evening. Lots of news from Mercury. We look forward to speaking to you again next quarter. Thank you.
This concludes today's conference call. Thank you for attending. You may now disconnect.